Loading
A phase 3 trial of Olomorasib, Pembrolizumab and Durvalumab in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06890598 by Eli Lilly and Company, with 700 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-05. Interventions recorded: Olomorasib, Pembrolizumab, Durvalumab and Placebo.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares Olomorasib, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.